Developing a therapeutic plan for treating MS: evidence for new treatments

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) necessitates individualized treatment strategies.
• Current disease-modifying therapies (DMTs) target relapsing forms of MS, with limited options for progressive stages.
• Effective management involves balancing treatment benefits against adverse effects.

Purpose of the Study:

• To provide clinicians with a comprehensive overview of MS treatment options.
• To guide the selection of appropriate DMTs based on disease course and patient preference.
• To inform about acute relapse management and complementary/alternative medicine considerations.

Main Methods:

• Review of current therapeutic guidelines and clinical trial data for MS treatments.
• Analysis of efficacy, safety profiles, and administration routes of available DMTs.
• Consideration of treatment strategies for acute relapses and complementary therapies.

Main Results:

• DMTs are approved for relapsing MS, with one agent for secondary progressive MS.
• Short-term steroids, plasma exchange, or IV immunoglobulin (IVIG) are options for acute relapses.
• Clinicians need to weigh benefits, risks, and patient preferences for optimal medication selection.

Conclusions:

• Individualized treatment plans are essential for managing multiple sclerosis.
• Informed patient-clinician discussion is key to selecting the most suitable therapy.
• Awareness of all treatment modalities, including complementary options, enhances patient care.